|
The drug, Adzenys XR-ODT, is approved for the treatment of Attention
Deficit Hyperactivity Disorder (ADHD) in patients aged six and
older. The drug is an orally disintegrating tablet and a
longer-acting version of amphetamine, a commonly prescribed ADHD
drug.
ADHD is a condition with symptoms such as poor concentration,
hyperactivity and learning difficulties.
The disorder affects about 4.1 percent of American adults aged 18
years and older in a given year and 9 percent of children aged 13-18
years, according to the National Institute of Mental Health.
The company said product launch and shipments will begin in the
second quarter of 2016.
The approval is backed by certain data which addresses issues raised
by the FDA when it rejected the drug in 2013.
RBC Capital analysts said the approval is an important event for
Neos on a product where they see an adjusted per-share value of $22
versus the existing equity value of about $10.
The Texas-based company, which debuted on July 23, is focused on
developing longer-acting treatments, particularly to address the
ADHD market.
[to top of second column] |
As of Wednesday's close, shares of the company were down 37 pct
since its debut.
(Reporting by Samantha Kareen Nair in Bengaluru; Editing by Sunil
Nair)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
